MVMarieke J A Verhagen

Marieke J A Verhagen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marieke J A Verhagen has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acquired haemophilia A: Balancing on the edge of haemostasis – Case series

    by Marieke J A Verhagen, Sanna R Rijpma, Saskia E M Schols

    Introduction: Emicizumab has recently been investigated for prophylactic use in patients with acquired haemophilia A. While it shows promising results in effectively reducing bleeding episodes, there remains a very delicate question concerning the risk of thromboembolic events. Recently published prospective studies reported thrombotic events in 4% to 8% of cases. However, these studies excluded patients with an increased thrombotic risk or those undergoing treatment for a thromboembolic disease, situations frequently occurring in this elderly patient group. Therefore, we urge clinicians to critically assess which patients would benefit from emicizumab treatment and which would not. Case series: Here, we present a case series from a Dutch haemophilia treatment centre that highlights the complexity of patients currently managed with acquired haemophilia A. The series discusses individual patient characteristics, underlying comorbidities, and responses to initiated therapy with bypassing agents and immunosuppressive therapy. The pros and cons of emicizumab therapy in these individual patients are discussed. Discussion: We suggest considering the use of emicizumab in patients with acquired haemophilia A through a personalised approach. This approach involves assessing thrombotic risk on one hand and focusing on controlling bleeding on the other. It should account for the need to rapidly eradicate the inhibitor in cases of acute bleeding necessitating bypassing agents. Alternatively, it should consider the possibility of postponing or reducing immunosuppressive therapy in frail patients without overt bleeding, for whom emicizumab presents an ideal prophylactic option.


  • Open Access

    Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review

    by Marieke J.A. Verhagen, Lars L.F.G. Valke, Saskia E.M. Schols